Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome

American Journal of Hematology

Volumn 84, Issue 5, 2009, Pages 314-315

  Yasukawa, Masaki ^a   Fujiwara, Hiroshi ^a   Ochi, Toshiki ^a   Suemori, Koichiro ^a   Narumi, Hiroshi ^a   Azuma, Taichi ^a   Kuzushima, Kiyotaka ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; CYSTEINYLMETHIONYLTHREONYLTRYPTOPHYLASPARAGINYLGLUTAMYLMETHIONYL ASPARAGINYLLEUCINE; CYTARABINE; DAUNORUBICIN; HEMOGLOBIN; HLA A ANTIGEN; HLA A2402 ANTIGEN; PEPTIDE VACCINE; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; AGED; APLASTIC ANEMIA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPLASIA; LETTER; LOW DRUG DOSE; MALE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION;

AGED; ANEMIA, APLASTIC; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OLIGOPEPTIDES; PEPTIDES; RECURRENCE; REMISSION INDUCTION; VACCINATION; WT1 PROTEINS;

EID: 65649130080     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21387     Document Type: Letter

References (10)

1. Xue S, Gao L, Gillmore R, et al. WT1-targeted immunotherapy of leukaemia. Blood Cells Mol Dis 2004;33:288-290.
2. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885-13890.
3. Mailänder V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004;18:165-166.
4. + T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007;13:4547-4555.
5. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111:236-242.
6. Kitawaki T, Kadowaki N, Kondo T, et al. Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole limpet hemocyanin-pulsed, donor-derived dendritic cell vaccine for acute myeloid leukemia. Am J Hematol 2008;83:315-317.
7. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-293. (Pubitemid 30017254)
8. Azuma T, Makita M, Ninomiya K, et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2002;116:601-603.
9. Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002;8:2626-2631.
10. Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003;78:56-61.